Should AbbVie break up Allergan? If it wants to make up for Humira, then yes, analyst says

Should AbbVie break up Allergan? If it wants to make up for Humira, then yes, analyst says

Source: 
Fierce Pharma
snippet: 

When AbbVie inked its $63 billion Allergan deal, one fear above all motivated the deal: Biosimilars to megablockbuster Humira, due stateside in 2023. But Allergan's best-selling Botox and other promising drugs may not be enough. What could help? Hiving off assets—or so figures one analyst who's called for Allergan selloffs before.